{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:02:10Z","timestamp":1787580130580,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":582,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["1R01 FD006323-01"],"award-info":[{"award-number":["1R01 FD006323-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VetDC, Inc"},{"DOI":"10.13039\/100012752","name":"Elanco Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["1R01 FD006323\u201001"],"award-info":[{"award-number":["1R01 FD006323\u201001"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012752","name":"Elanco Animal Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dogs with lymphoma that fail cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (CHOP) before completion of their protocol are commonly thought to have poor long-term outcome, but no previous studies have evaluated the effect of early relapse on progression-free interval (PFI) or overall survival time (OST) for patients undergoing rescue chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Correlate rescue treatment outcomes in dogs with multicentric lymphoma with outcomes after 1st-line CHOP chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected from 6 previous retrospective or prospective studies in 187 dogs with multicentric lymphoma that received 1st-line CHOP chemotherapy and then received either lomustine (CCNU), L-asparaginase and prednisone (LAP), or rabacfosadine (RAB, Tanovea), with or without prednisone or L-asparaginase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PFI after initiation of CHOP chemotherapy was significantly associated with response rate postprogression, PFI, and postrescue survival time (ST) for both rescue protocols. Immunophenotype (B- vs T-cell) was not significantly associated with response, PFI or OST for LAP but was significantly associated with response and PFI for RAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dogs that experience short PFI during or after 1st-line CHOP chemotherapy had lower response rates to rescue treatment, with shorter PFI and ST. Immunophenotype did not significantly affect outcome with LAP but was associated with PFI for RAB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.17139","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T02:38:24Z","timestamp":1720060704000},"page":"2282-2292","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early progression during or after cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy indicates poor outcome with rescue protocols in dogs with multicentric lymphoma"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2630-8674","authenticated-orcid":false,"given":"Ashley S.","family":"Parker","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-8298","authenticated-orcid":false,"given":"Jenna H.","family":"Burton","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin M.","family":"Curran","sequence":"additional","affiliation":[{"name":"Carlson College of Veterinary Medicine, Oregon State University , Corvallis, Oregon,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Wolf-Ringwall","sequence":"additional","affiliation":[{"name":"Red River Animal Emergency Hospital & Referral Center , Fargo, North Dakota,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7767","authenticated-orcid":false,"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"2026020304091100100_jvim17139-bib-0001","first-page":"688","article-title":"Withrow & MacEwen's Small Animal Clinical Oncology","author":"Vail","year":"2020","edition":"6th ed."},{"key":"2026020304091100100_jvim17139-bib-0002","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2460\/javma.238.4.501","article-title":"Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007)","volume":"238","author":"Flory","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304091100100_jvim17139-bib-0003","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1939-1676.2007.tb02938.x","article-title":"Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma","volume":"21","author":"Saba","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0004","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/jvim.15723","article-title":"Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs","volume":"34","author":"Cawley","year":"2020","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1476-5829.2012.00324.x","article-title":"Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma","volume":"11","author":"Burton","year":"2013","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/vco.12163","article-title":"Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"Curran","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/vco.12553","article-title":"Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with na\u00efve B-cell lymphoma treated with a 19-week CHOP protocol","volume":"18","author":"Wolf-Ringwall","year":"2020","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0008","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jvim.16341","article-title":"Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma","volume":"36","author":"Weishaar","year":"2022","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0009","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/vco.12337","article-title":"Rabacfosadine for relapsed canine B-cell lymphoma: efficacy and adverse event profiles of 2 different doses","volume":"16","author":"Saba","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0010","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0012","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1939-1676.2007.tb01959.x","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"Hosoya","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5326\/0430027","article-title":"Phase II clinical trial of combination chemotherapy with dexamethasone for lymphoma in dogs","volume":"43","author":"Greenberg","year":"2007","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304091100100_jvim17139-bib-0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1939-1676.1993.tb01021.x","article-title":"Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma","volume":"7","author":"Keller","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0015","first-page":"196","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"Sorenmo","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0016","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tvjl.2013.04.022","article-title":"Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results","volume":"197","author":"Zandvliet","year":"2013","journal-title":"Vet J"},{"key":"2026020304091100100_jvim17139-bib-0017","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1939-1676.2005.tb02753.x","article-title":"Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?","volume":"19","author":"MacDonald","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020304091100100_jvim17139-bib-0018","first-page":"4379","article-title":"Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines","volume":"46","author":"Teicher","year":"1986","journal-title":"Cancer Res"},{"key":"2026020304091100100_jvim17139-bib-0019","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0014-2964(78)90025-7","article-title":"Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia","volume":"14","author":"Wampler","year":"1978","journal-title":"Eur J Cancer"},{"key":"2026020304091100100_jvim17139-bib-0020","doi-asserted-by":"crossref","first-page":"72608","DOI":"10.18632\/oncotarget.11618","article-title":"Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells","volume":"7","author":"Oppermann","year":"2016","journal-title":"Oncotarget"},{"key":"2026020304091100100_jvim17139-bib-0021","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ccell.2018.11.002","article-title":"Lymphocyte-specific chromatin accessibility pre-determines glucocorticoid resistance in acute lymphoblastic leukemia","volume":"34","author":"Jing","year":"2018","journal-title":"Cancer Cell"},{"key":"2026020304091100100_jvim17139-bib-0022","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/carcin\/bgl218","article-title":"Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice","volume":"28","author":"Hansen","year":"2007","journal-title":"Carcinogenesis"},{"key":"2026020304091100100_jvim17139-bib-0023","first-page":"2059","article-title":"O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma: implications for treatment with alkylating agents","volume":"5","author":"Dolan","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2026020304091100100_jvim17139-bib-0024","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/vco.12318","article-title":"LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma","volume":"16","author":"Brown","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0025","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/vco.12430","article-title":"Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs","volume":"16","author":"Morgan","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026020304091100100_jvim17139-bib-0026","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/vco.12768","article-title":"Prognostic indicators for na\u00efve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy","volume":"20","author":"Blaxill","year":"2022","journal-title":"Vet Comp Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2282\/66663398\/jvim17139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/38\/4\/2282\/66663398\/jvim17139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:09:25Z","timestamp":1770109765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/38\/4\/2282\/8448709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.17139","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"2023-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}